195 related articles for article (PubMed ID: 22927431)
1. RIP1 protein-dependent assembly of a cytosolic cell death complex is required for inhibitor of apoptosis (IAP) inhibitor-mediated sensitization to lexatumumab-induced apoptosis.
Basit F; Humphreys R; Fulda S
J Biol Chem; 2012 Nov; 287(46):38767-77. PubMed ID: 22927431
[TBL] [Abstract][Full Text] [Related]
2. RIP1 is required for IAP inhibitor-mediated sensitization for TRAIL-induced apoptosis via a RIP1/FADD/caspase-8 cell death complex.
Abhari BA; Cristofanon S; Kappler R; von Schweinitz D; Humphreys R; Fulda S
Oncogene; 2013 Jul; 32(27):3263-73. PubMed ID: 22890322
[TBL] [Abstract][Full Text] [Related]
3. Cooperative TRAIL production mediates IFNα/Smac mimetic-induced cell death in TNFα-resistant solid cancer cells.
Roesler S; Eckhardt I; Wolf S; Fulda S
Oncotarget; 2016 Jan; 7(4):3709-25. PubMed ID: 26788912
[TBL] [Abstract][Full Text] [Related]
4. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO).
Ng CP; Bonavida B
Mol Cancer Ther; 2002 Oct; 1(12):1051-8. PubMed ID: 12481428
[TBL] [Abstract][Full Text] [Related]
5. Identification of RIP1 as a critical mediator of Smac mimetic-mediated sensitization of glioblastoma cells for Drozitumab-induced apoptosis.
Cristofanon S; Abhari BA; Krueger M; Tchoghandjian A; Momma S; Calaminus C; Vucic D; Pichler BJ; Fulda S
Cell Death Dis; 2015 Apr; 6(4):e1724. PubMed ID: 25880091
[TBL] [Abstract][Full Text] [Related]
6. RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis.
Löder S; Fakler M; Schoeneberger H; Cristofanon S; Leibacher J; Vanlangenakker N; Bertrand MJ; Vandenabeele P; Jeremias I; Debatin KM; Fulda S
Leukemia; 2012 May; 26(5):1020-9. PubMed ID: 22173242
[TBL] [Abstract][Full Text] [Related]
7. Smac mimetic triggers necroptosis in pancreatic carcinoma cells when caspase activation is blocked.
Hannes S; Abhari BA; Fulda S
Cancer Lett; 2016 Sep; 380(1):31-8. PubMed ID: 27267809
[TBL] [Abstract][Full Text] [Related]
8. Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib.
Luster TA; Carrell JA; McCormick K; Sun D; Humphreys R
Mol Cancer Ther; 2009 Feb; 8(2):292-302. PubMed ID: 19174554
[TBL] [Abstract][Full Text] [Related]
9. Cellular IAP proteins and LUBAC differentially regulate necrosome-associated RIP1 ubiquitination.
de Almagro MC; Goncharov T; Newton K; Vucic D
Cell Death Dis; 2015 Jun; 6(6):e1800. PubMed ID: 26111062
[TBL] [Abstract][Full Text] [Related]
10. TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors.
Stadel D; Mohr A; Ref C; MacFarlane M; Zhou S; Humphreys R; Bachem M; Cohen G; Möller P; Zwacka RM; Debatin KM; Fulda S
Clin Cancer Res; 2010 Dec; 16(23):5734-49. PubMed ID: 20940278
[TBL] [Abstract][Full Text] [Related]
11. Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin.
Belyanskaya LL; Marti TM; Hopkins-Donaldson S; Kurtz S; Felley-Bosco E; Stahel RA
Mol Cancer; 2007 Oct; 6():66. PubMed ID: 17953743
[TBL] [Abstract][Full Text] [Related]
12. Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma.
Engesæter B; Engebraaten O; Flørenes VA; Mælandsmo GM
PLoS One; 2012; 7(9):e45492. PubMed ID: 23029050
[TBL] [Abstract][Full Text] [Related]
13. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
Izeradjene K; Douglas L; Delaney A; Houghton JA
Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
[TBL] [Abstract][Full Text] [Related]
14. cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production.
Vanlangenakker N; Vanden Berghe T; Bogaert P; Laukens B; Zobel K; Deshayes K; Vucic D; Fulda S; Vandenabeele P; Bertrand MJ
Cell Death Differ; 2011 Apr; 18(4):656-65. PubMed ID: 21052097
[TBL] [Abstract][Full Text] [Related]
15. Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-κB-dependent manner.
Wagner L; Marschall V; Karl S; Cristofanon S; Zobel K; Deshayes K; Vucic D; Debatin KM; Fulda S
Oncogene; 2013 Feb; 32(8):988-97. PubMed ID: 22469979
[TBL] [Abstract][Full Text] [Related]
16. Enhanced metastasis suppression by targeting TRAIL receptor 2 in a murine model of triple-negative breast cancer.
Malin D; Chen F; Schiller C; Koblinski J; Cryns VL
Clin Cancer Res; 2011 Aug; 17(15):5005-15. PubMed ID: 21653692
[TBL] [Abstract][Full Text] [Related]
17. TWEAK induces apoptosis through a death-signaling complex comprising receptor-interacting protein 1 (RIP1), Fas-associated death domain (FADD), and caspase-8.
Ikner A; Ashkenazi A
J Biol Chem; 2011 Jun; 286(24):21546-54. PubMed ID: 21525013
[TBL] [Abstract][Full Text] [Related]
18. RIP1-dependent Bid cleavage mediates TNFα-induced but Caspase-3-independent cell death in L929 fibroblastoma cells.
Chen G; Cheng X; Zhao M; Lin S; Lu J; Kang J; Yu X
Apoptosis; 2015 Jan; 20(1):92-109. PubMed ID: 25398540
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of lexatumumab-induced apoptosis in human solid cancer cells by Cisplatin in caspase-dependent manner.
Wu XX; Kakehi Y
Clin Cancer Res; 2009 Mar; 15(6):2039-47. PubMed ID: 19276256
[TBL] [Abstract][Full Text] [Related]
20. Smac mimetic sensitizes renal cell carcinoma cells to interferon-α-induced apoptosis.
Reiter M; Eckhardt I; Haferkamp A; Fulda S
Cancer Lett; 2016 May; 375(1):1-8. PubMed ID: 26912071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
